 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Increasing numbers of company initiatives across the world coupled with the benefits
  of gene panels are the major factors that help in fostering the gene panel market.
  Moreover, increasing adoption of genetic testing, technological advancements such
  as the Next Generation Sequencing System, and the ...


Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research(R)

---
- Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for
  new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
- ''
- " Swiss pharma giant Roche Holding AGs RHHBY performance in the second quarter,
  and consequently in the first half of 2021, gained ..."


Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars

---
- GenMark Diagnostics (NASDAQ:GNMK) and Pulmonx (NASDAQ:LUNG) are both small-cap medical
  companies, but which is the superior investment? We will contrast the two companies
  based on the strength of their dividends, analyst recommendations, earnings, institutional
  ownership, valuation, profitability ...


GenMark Diagnostics (NASDAQ:GNMK) & Pulmonx (NASDAQ:LUNG) Head to Head Comparison

---
- EMC Capital Management raised its holdings in shares of GenMark Diagnostics, Inc.
  (NASDAQ:GNMK) by 8.9% in the first quarter, according to the company in its most
  recent disclosure with the Securities and Exchange Commission. The fund owned 121,023
  shares of the medical equipment providers stock ...


GenMark Diagnostics, Inc. (NASDAQ:GNMK) Holdings Boosted by EMC Capital Management

---
- Paradigm Capital Management Inc. NY boosted its stake in shares of GenMark Diagnostics,
  Inc. (NASDAQ:GNMK) by 18.1% during the 1st quarter, Holdings Channel reports. The
  institutional investor owned 733,300 shares of the medical equipment providers stock
  after buying an additional 112,500 shares ...


Paradigm Capital Management Inc. NY Buys 112,500 Shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK)

---
- Chicago Capital Management LLC purchased a new position in GenMark Diagnostics,
  Inc. (NASDAQ:GNMK) during the 1st quarter, according to its most recent disclosure
  with the Securities and Exchange Commission (SEC). The institutional investor purchased
  318,113 shares of the medical equipment providers...


Chicago Capital Management LLC Takes Position in GenMark Diagnostics, Inc. (NASDAQ:GNMK)

---
- GenMark Diagnostics, Inc. (NASDAQ:GNMK) has earned a consensus recommendation of
  Hold from the six brokerages that are covering the company, Marketbeat reports.
  One research analyst has rated the stock with a sell rating and five have issued
  a hold rating on the company. The average ...


GenMark Diagnostics, Inc. (NASDAQ:GNMK) Receives Consensus Recommendation of "Hold" from Analysts

---
- Motus GI (NASDAQ:MOTS) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap
  medical companies, but which is the superior business? We will contrast the two
  companies based on the strength of their valuation, earnings, profitability, dividends,
  analyst recommendations, risk and institutional ...


Motus GI (NASDAQ:MOTS) versus GenMark Diagnostics (NASDAQ:GNMK) Financial Survey

---
- JPMorgan Chase  Co. grew its holdings in shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK)
  by 21.0% during the fourth quarter, according to the company in its most recent
  Form 13F filing with the Securities and Exchange Commission. The fund owned 31,404
  shares of the medical equipment provider...


GenMark Diagnostics, Inc. (NASDAQ:GNMK) Stake Raised by JPMorgan Chase & Co.

---
- Motus GI (NASDAQ:MOTS) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap
  medical companies, but which is the superior stock? We will compare the two businesses
  based on the strength of their earnings, risk, valuation, profitability, dividends,
  analyst recommendations and institutional ...


Motus GI (NASDAQ:MOTS) vs. GenMark Diagnostics (NASDAQ:GNMK) Head-To-Head Contrast

GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing its sensor detection technology. The Company’s electrochemical technology enables the detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified deoxyribonucleic acid (DNA) sample, its XT-8 System produces results. The XT-8 System supports up to 24 test cartridges, which can be run independently, and are targeted for hospitals and reference laboratories. The Company is also developing its next-generation platform, the AD-8 System, to integrate DNA amplification with its sensor detection technology to enable technicians to place a minimally prepared patient sample into its test cartridge.

Market Cap	$1.77B
Volume (M)	3.83M
52-Wk High	$24.25
52-Wk Low	$8.47

Current Price	$24.04
Prev Close	$24.04
Open	$24.04
Dividend Yield	N/A
50-Day Moving Average	$22.12
Beta	0.32
Avg. Volume	5.1M
PE Ratio	-84.89

52-Week High	$24.25
52-Week Low	$8.47
Market Capitalization	$1.77B
EPS	N/A
Price to Book	18.36
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

GNMK GenMark Diagnostics, Inc.

About

Feed

News

Fundamentals